A Phase 2 interventional study of S-Ibuprofen and Vehicle in Pain, Acute, sponsored by Aponia Laboratories, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-25.
Sponsored by Aponia Laboratories, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.
Among the 351 studies in Acute Pain with a site in United States, this one is the 56th largest by enrollment of the 320 interventional ones that give a count, is one of 34 that started in 2018, is one of 54 in phase 2, and was the 164th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 63 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 34 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 84 across the 320 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 132 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 351 have an industry lead sponsor. The 10 most frequent:
Aponia Laboratories, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Aponia Laboratories, Inc. has 2 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
31 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%
The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S-Ibuprofen Topical Gel 5%
Drug: S-Ibuprofen
Vehicle Topical Gel
Drug: Vehicle
Topical Gel 5%
Vehicle Gel
Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero
The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).
Time frame: 0-24 hours.
SPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.
Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.
Time frame: From 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28,36-48, and 0-48 hours post-T0. Time point i included 1, 2, 3, 4, 5, 6 (pre-dose), 7, 8, 9, 10, 11, 12 (pre-dose), 16, 18 (pre-dose), 20, and 24 (pre-dose) hours after the first dose.
Sum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval
Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.
Time frame: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48, and 0-48 post T0
Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero
Total relief with movement (TOTPAR) 0-6 hours post time zero TOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief. Categorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale "0=no relief," "1=a little relief," "2=some relief," "3=a lot of relief," or "4=complete relief" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.
Time frame: 0-6 hours
Subject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero
Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment). Subject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.
Time frame: 48 hours post time zero
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.
Time frame: Up to Day 7
This was a Phase 2/3, single-center study conducted in USA
| Milestone | Active Arm | Placebo Arm |
|---|---|---|
| Started | 126 | 125 |
| Completed | 123 | 122 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).
| score on a scale*hours | Active Arm | Placebo Arm |
|---|---|---|
| Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero | -33.09 ± 31.311 | -29.09 ± 29.763 |
Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.
| score on a scale*hours | Active Arm | Placebo Arm |
|---|---|---|
| 0-6 hours | -4.82 ± 5.478 | -4.06 ± 5.807 |
| 6-12 hours | -8.98 ± 8.583 | -7.73 ± 8.412 |
| 0-12 hours | -13.80 ± 13.435 | -11.79 ± 13.682 |
| 12-24 hours | -19.29 ± 18.868 | -17.30 ± 17.338 |
| 24-36 hours | -26.55 ± 18.582 | -24.35 ± 18.807 |
| 24-48 hours | -60.37 ± 38.168 | -54.61 ± 38.604 |
| 0-36 hours | -59.64 ± 48.384 | -53.44 ± 46.530 |
| 36-48 hours | -33.82 ± 20.293 | -30.26 ± 20.794 |
| 0-48 hours | -93.47 ± 66.331 | -83.71 ± 64.201 |
Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.
| score on a scale*hours | Active Arm | Placebo Arm |
|---|---|---|
| 0-6 hours | -3.81 ± 6.218 | -3.33 ± 5.957 |
| 6-12 hours | -7.75 ± 9.893 | -6.48 ± 8.796 |
| 0-12 hours | -11.55 ± 15.446 | -9.81 ± 14.302 |
| 12-24 hours | -17.20 ± 20.476 | -14.91 ± 19.369 |
| 0-24 hours | -28.75 ± 34.920 | -24.72 ± 32.365 |
| 24-36 hours | -23.33 ± 21.209 | -19.95 ± 22.555 |
| 24-48 hours | -53.58 ± 44.528 | -44.77 ± 44.732 |
| 0-36 hours | -52.08 ± 54.840 | -44.68 ± 53.031 |
| 36-48 hours | -30.25 ± 23.947 | -24.82 ± 23.171 |
| 0-48 hours | -82.33 ± 76.936 | -69.49 ± 73.804 |
Total relief with movement (TOTPAR) 0-6 hours post time zero TOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief. Categorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale "0=no relief," "1=a little relief," "2=some relief," "3=a lot of relief," or "4=complete relief" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.
| score on a scale*hours | Active Arm | Placebo Arm |
|---|---|---|
| Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero | 4.06 ± 3.435 | 3.61 ± 3.978 |
Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment). Subject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.
| Participants | Active Arm | Placebo Arm |
|---|---|---|
| Original Categories - Poor | 44 | 50 |
| Original Categories - Fair | 48 | 47 |
| Original Categories - Good | 25 | 21 |
| Original Categories - Very good | 9 | 5 |
| Original Categories - Excellent | 0 | 1 |
| Dichotomized Categories - Poor/fair | 92 | 97 |
| Dichotomized Categories - Good/very good/excellent | 34 | 27 |
TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.
| participants | Active Arm | Placebo Arm |
|---|---|---|
| Subjects with any TEAE | 125 | 121 |
| Subjects with any treatment-related TEAEs | 124 | 120 |
| Subjects with TEAEs leading to discontinuation | 2 | 2 |
| Subjects with SAEs | 0 | 0 |
| TEAE with mild in severity | 119 | 115 |
| TEAE with moderate in severity | 6 | 4 |
| TEAE with Severe in severity | 0 | 2 |
Collected over Up to Day 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Arm | 0/126 (0%) | 0/126 (0%) | 123/126 (97.6%) |
| Placebo Arm | 0/125 (0%) | 0/125 (0%) | 117/125 (93.6%) |
| Event | Active Arm | Placebo Arm |
|---|---|---|
| application site erythemaGeneral disorders | 123/126 | 117/125 |
| application site pruritusGeneral disorders | 62/126 | 76/125 |
| application site painGeneral disorders | 70/126 | 13/125 |
| skin exfoliationSkin and subcutaneous tissue disorders | 27/126 | 4/125 |
| application site indurationGeneral disorders | 25/126 | 21/125 |
| musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 8/126 | 8/125 |
| Age, Continuous(years) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| Mean | 28.2 ± 10.41 | 30.6 ± 10.37 | 29.4 ± 10.44 |
| Sex: Female, Male(Participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| Female | 73 | 68 | 141 |
| Male | 53 | 57 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 24 | 24 | 48 |
| Not Hispanic or Latino | 102 | 101 | 203 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 6 | 9 | 15 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 3 |
| White | 102 | 102 | 204 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 16 | 9 | 25 |
| Region of Enrollment(participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| United States | 126 | 125 | 251 |
| Body Mass Index (BMI)(kg/m^2) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| Mean | 24.01 ± 3.146 | 24.55 ± 3.082 | 24.28 ± 3.120 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Apr 2019, 14 months.
Results were first posted in Jan 2022, 2 years 9 months after primary completion.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 14 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexibuprofen
Aponia Laboratories, Inc.